United States SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)*

Revolution Medicines, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 per share (Title of Class of Securities)

> 76155X100 (CUSIP Number)

December 31, 2023 (Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 \Box Rule 13d-1(b)

 \boxtimes Rule 13d-1(c)

 \Box Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 76155X100

1.					
BB Biotech AG					
2. Check the Appropriate Box if a Member of a Group (See Instructions)					
	(a) \boxtimes (b) \square				
3.					
4.	Citizenship or Place of Organization				
	Switzer	land			
		5.	Sole Voting Power		
Nu	mber of		0		
S	Shares Beneficially Owned by Each Reporting Person with:		Shared Voting Power		
			5,046,700		
			Sole Dispositive Power		
I			0		
			Shared Dispositive Power		
			5,046,700		
9. Aggregate Amount Beneficially Owned by Each Reporting Person			mount Beneficially Owned by Each Reporting Person		
	5,046,700				
10.	Check i	f the	Aggregate Amount in Row (9) Excludes Certain Shares		
11.					
3.1%					
12.	Type of	Rep	orting Person (See Instructions)		
	HC, CO				

CUSIP No. 76155X100

1.	Names of Reporting Persons					
	wth N.V.					
2.	Check t	eck the Appropriate Box if a Member of a Group (See Instructions)				
	(a) \boxtimes (b) \square					
3.	SEC Use Only					
4.	Citizens	Citizenship or Place of Organization				
Curaçao						
		5.	Sole Voting Power			
Nu	mber of		0			
	hares	6.	Shared Voting Power			
	neficially					
	Owned by		0			
	Each	7.	Sole Dispositive Power			
	eporting					
	Person		0			
	with:	8.	Shared Dispositive Power			
			0			
9.	Aggrega	ate A	mount Beneficially Owned by Each Reporting Person			
	0					
10.	Check i	f the	Aggregate Amount in Row (9) Excludes Certain Shares			
	_					
11.	Percent	Percent of Class Represented by amount in Row (9)				
10						
12. Type of Reporting Person (See Instructions)			orting Person (See Instructions)			
	CO					

CUSIP No. 76155X100

1.	1. Names of Reporting Persons					
Biotech Target N.V.						
2.	Check t	ppropriate Box if a Member of a Group (See Instructions)				
2	(a) 🗵					
3.	3. SEC Use Only					
4.	Citizens	Citizenship or Place of Organization				
	G					
	Curaçao					
		5.	Sole Voting Power			
Nu	mber of		0			
S	Shares Beneficially Owned by Each Reporting Person with:		Shared Voting Power			
			5,046,700			
			Sole Dispositive Power			
			0			
			Shared Dispositive Power			
		8.	Shared Dispositive Fower			
			5,046,700			
9.	Aggrega	ate A	mount Beneficially Owned by Each Reporting Person			
	5,046,7	00				
10.			Aggregate Amount in Row (9) Excludes Certain Shares			
	_					
11. Percent of Class Represented by amount in Row (9)			lass Represented by amount in Row (9)			
3.1%						
12. Type of Reporting Person (See Instructions)			orting Person (See Instructions)			
	СО					

Item 1

- 1(a) Name of Issuer: Revolution Medicines, Inc.
- 1(b) Address of Issuer's Principal Executive Offices:
 - 700 Saginaw Drive, Redwood City, California 94063, United States of America

Item 2

2(a) Name of Person Filing: BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiaries, Biotech Growth N.V. ("Biotech Growth") and Biotech Target N.V. ("Biotech Target")

- 2(b) Address of Principal Business Office or, if none, Residence: BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao
- 2(c) Citizenship: BB Biotech AG: Switzerland

Biotech Growth N.V.: Curaçao

Biotech Target N.V.: Curaçao

- 2(d) Title of Class of Securities: Common Stock, par value \$0.0001 per share
- 2(e) CUSIP Number: 76155X100

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item

- 1.
 - (a) Amount beneficially owned: 5,046,700
 - (b) Percent of class: 3.1%
 - (c) Number of shares as to which the person has:
 - (i) Sole power to vote or to direct the vote 0
 - (ii) Shared power to vote or to direct the vote 5,046,700
 - (iii) Sole power to dispose or to direct the disposition of 0
 - (iv) Shared power to dispose or to direct the disposition of 5,046,700

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following \boxtimes .

This statement is filed jointly by BB Biotech, Biotech Growth and Biotech Target. Biotech Growth and Biotech Target are wholly-owned subsidiaries of BB Biotech.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

Date: February 6, 2024	By:	/s/ Martin Gubler
		Signatory Authority
	Name:	Martin Gubler
	Title:	Signatory Authority
Date: February 6, 2024	By:	/s/ Ivo Betschart
•		Signatory Authority
	Name:	Ivo Betschart
	Title:	Signatory Authority
Biotech Growth N.V.		
Date: February 6, 2024	By:	/s/ Jan Bootsma
		Signatory Authority
	Name:	Jan Bootsma
	Title:	Signatory Authority
Date: February 6, 2024	By:	/s/ Hugo van Neutegem
	·	Signatory Authority
	Name:	Hugo van Neutegem
	Title:	Signatory Authority
	7 of 10	

Biotech Target N.V.			
Date: February 6, 2024	By:	/s/ Jan Bootsma	
		Signatory Authority	
	Name:	Jan Bootsma	
	Title:	Signatory Authority	
Date: February 6, 2024	By:	/s/ Hugo van Neutegem	
		Signatory Authority	
	Name:	Hugo van Neutegem	
	Title:	Signatory Authority	
	8 of 10		

<u>Exhibit A</u>

Joint Filing Statement

We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

BB Biotech AG

Date: February 6, 2024	By:	/s/ Martin Gubler
		Signatory Authority
	Name:	Martin Gubler
	Title:	Signatory Authority
Date: February 6, 2024	By:	/s/ Ivo Betschart
v ,		Signatory Authority
	Name:	Ivo Betschart
	Title:	Signatory Authority
Biotech Growth N.V.		
Date: February 6, 2024	By:	/s/ Jan Bootsma
		Signatory Authority
	Name:	Jan Bootsma
	Title:	Signatory Authority
Date: February 6, 2024	By:	/s/ Hugo van Neutegem
v		Signatory Authority
	Name:	Hugo van Neutegem
	Title:	Signatory Authority
	0 of 10	

Biotech Target N.V.			
Date: February 6, 2024	By:	/s/ Jan Bootsma	
		Signatory Authority	
	Name:	Jan Bootsma	
	Title:	Signatory Authority	
Date: February 6, 2024	By:	/s/ Hugo van Neutegem	
		Signatory Authority	
	Name:	Hugo van Neutegem	
	Title:	Signatory Authority	
	10 of 10		